Polyhexanide

ApprovedSmall molecule

SSwiss Paraplegic Research, Nottwil

Polyhexanide is one of 3 small molecule programs targeting Staphylococcus Aureus. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Staphylococcus AureusCompleted

Staphylococcus AureusApproved

Completed

Competition

Competitive Landscape

2 competitors in Staphylococcus Aureus

#DrugCompanyPhaseTrials

Mupirocin and Chlorhexidine

JJohns Hopkins University

Approved

2 2

Polyhexanide

SSwiss Paraplegic Research, Nottwil

Approved

1 3

AZD7760

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Staphylococcus Aureus1 trial

Surgical Prophylaxis: Assessing Decolonization Efficacy of Polyhexanide Versus Mupirocin and Chlorhexidine in Decolonizing Staphylococcus Aureus Preoperatively in Elective Spine Surgery (SPADE): A Pilot Randomized Controlled Trial

Completed·SSwiss Paraplegic Research, Nottwil·Approved·NCT06633588·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Polyhexanide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Polyhexanide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Polyhexanide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Swiss Paraplegic Research, Nottwil company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SSwiss Paraplegic Research, Nottwil

Polyhexanide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Staphylococcus Aureus1 trial

References

Drug Info

Quick Facts

Related News